Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 2582179, 5 pages
Research Article

BRAF 1799T>A Mutation Frequency in Mexican Mestizo Patients with Papillary Thyroid Cancer

1Unidad de Genética, Hospital General de México, Dr. Balmis 148, Cuauhtémoc, 06720 México City, Mexico
2Servicio de Cirugía, Hospital General de México, Dr. Balmis 148, Cuauhtémoc, 06720 México City, Mexico
3Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del IPN, Av. Instituto Politécnico Nacional 2508, San Pedro Zacatenco, 07360 México City, Mexico
4Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina-IPN, Plan de San Luis y Díaz Mirón s/n, Miguel Hidalgo, 11340 México City, Mexico
5Catedrático CONACyT, Unidad de Investigación Médica en Epidemiología Clínica, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, IMSS, Av. Cuauhtémoc 330, Cuauhtémoc, 06270 México City, Mexico

Correspondence should be addressed to Fernando Fernández-Ramírez; xm.manu.saicneic@zednanreff

Received 1 December 2017; Revised 19 February 2018; Accepted 22 February 2018; Published 2 April 2018

Academic Editor: Salvatore Gallone

Copyright © 2018 Fernando Fernández-Ramírez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Thyroid cancer is the most frequent endocrine malignancy, and its incidence and prevalence are increasing worldwide. Despite its generally good prognosis, the observed mortality rates are higher in the less-developed regions. This indicates that timely diagnosis and appropriate initial management of this disease are important to achieve a positive outcome. We performed an observational study in order to describe the frequency of the BRAF 1799T>A mutation in Mexican mestizo patients with thyroid nodules, a scarcely studied ethnic group with large populations. Competitive allele-specific Taqman PCR was performed in 147 samples of thyroid tissue DNA obtained from patients histologically diagnosed with papillary thyroid cancer (PTC), colloid goiters, and follicular adenomas. The BRAF 1799T>A mutation frequency was 61.1% in PTC samples ( = 4.99 × 10−11). Potential diagnostic values were as follows: sensitivity, 61.1%; specificity, 96%; PPV, 94.2%; NPV, 69.5%; accuracy, 77.9%. Taking into account the fact that this mutation is not frequently found in cytologically indeterminate nodules, we suggest that the BRAF mutational analysis should be implemented in the clinical setting along with other diagnostic criteria such as USG, in order to contribute to diagnosis and to surgical decision-making during the initial management of thyroid nodules in Mexican public hospitals.